{"id":"https://openalex.org/W7225320089","doi":"https://doi.org/10.1001/jamaoncol.2026.4471","title":"Evolving First-Line Treatment Strategies in ERBB2 -Positive Metastatic Breast Cancer","display_name":"Evolving First-Line Treatment Strategies in ERBB2 -Positive Metastatic Breast Cancer","publication_year":2026,"publication_date":"2026-11-05","ids":{"openalex":"https://openalex.org/W7225320089","doi":"https://doi.org/10.1001/jamaoncol.2026.4471","pmid":"https://pubmed.ncbi.nlm.nih.gov/42986620"},"language":"en","primary_location":{"id":"doi:10.1001/jamaoncol.2026.4471","doi":"https://doi.org/10.1001/jamaoncol.2026.4471","is_oa":false,"landing_page_url":"https://doi.org/10.1001/jamaoncol.2026.4471","pdf_url":null,"source":{"id":"https://openalex.org/S2756165422","display_name":"JAMA Oncology","issn_l":"2374-2437","issn":["2374-2437","2374-2445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320259","host_organization_name":"American Medical Association","host_organization_lineage":["https://openalex.org/P4310320259"],"host_organization_lineage_names":["American Medical Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JAMA Oncology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5160774703","display_name":"Yu Zong","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yu Zong","raw_affiliation_strings":["Department of Medicine, Division of Oncology, University of North Carolina, Chapel Hill"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Division of Oncology, University of North Carolina, Chapel Hill","institution_ids":["https://openalex.org/I114027177"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041777150","display_name":"LA Carey","orcid":"https://orcid.org/0000-0003-2388-4649","observed_orcids":["https://orcid.org/0000-0003-2388-4649"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lisa A. Carey","raw_affiliation_strings":["Department of Medicine, Division of Oncology, University of North Carolina, Chapel Hill"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Division of Oncology, University of North Carolina, Chapel Hill","institution_ids":["https://openalex.org/I114027177"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5000553093","display_name":"Yara George Abdou","orcid":"https://orcid.org/0000-0002-4827-8613","observed_orcids":["https://orcid.org/0000-0002-4827-8613"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yara Abdou","raw_affiliation_strings":["Department of Medicine, Division of Oncology, University of North Carolina, Chapel Hill"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Division of Oncology, University of North Carolina, Chapel Hill","institution_ids":["https://openalex.org/I114027177"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I114027177"],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9932000041007996,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9932000041007996,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.003599999938160181,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/her2-positive-metastatic-breast-cancer","display_name":"HER2-positive metastatic breast cancer","score":0.9350000023841858},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.8659999966621399},{"id":"https://openalex.org/keywords/trastuzumab-deruxtecan","display_name":"trastuzumab deruxtecan","score":0.9169999957084656},{"id":"https://openalex.org/keywords/pertuzumab","display_name":"pertuzumab","score":0.9589999914169312},{"id":"https://openalex.org/keywords/dual-her2-blockade","display_name":"dual HER2 blockade","score":0.75},{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.7480000257492065},{"id":"https://openalex.org/keywords/maintenance-therapy","display_name":"maintenance therapy","score":0.7369999885559082},{"id":"https://openalex.org/keywords/cdk4-6-inhibitors","display_name":"CDK4/6 inhibitors","score":0.8830000162124634},{"id":"https://openalex.org/keywords/endocrine-therapy","display_name":"endocrine therapy","score":0.9169999957084656},{"id":"https://openalex.org/keywords/chemotherapy-free-regimen","display_name":"chemotherapy-free regimen","score":0.7319999933242798},{"id":"https://openalex.org/keywords/treatment-sequencing","display_name":"treatment sequencing","score":0.8349999785423279},{"id":"https://openalex.org/keywords/circulating-tumor-dna","display_name":"circulating tumor DNA","score":0.9950000047683716},{"id":"https://openalex.org/keywords/biomarker-guided-therapy","display_name":"biomarker-guided therapy","score":0.6539999842643738}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9200999736785889},{"id":"https://openalex.org/C2781164504","wikidata":"https://www.wikidata.org/wiki/Q1998021","display_name":"Pertuzumab","level":5,"score":0.8306000232696533},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.788100004196167},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.6995999813079834},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6395000219345093},{"id":"https://openalex.org/C2779343474","wikidata":"https://www.wikidata.org/wiki/Q3109175","display_name":"Context (archaeology)","level":2,"score":0.5687000155448914},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5131000280380249},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.5037999749183655},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.4948999881744385},{"id":"https://openalex.org/C2780275930","wikidata":"https://www.wikidata.org/wiki/Q1628266","display_name":"Hormone therapy","level":4,"score":0.4189999997615814},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.400299996137619},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3926999866962433},{"id":"https://openalex.org/C2778283404","wikidata":"https://www.wikidata.org/wiki/Q6736822","display_name":"Maintenance therapy","level":3,"score":0.38190001249313354},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.3797999918460846},{"id":"https://openalex.org/C2778311097","wikidata":"https://www.wikidata.org/wiki/Q5903784","display_name":"Hormonal therapy","level":4,"score":0.31529998779296875},{"id":"https://openalex.org/C23589133","wikidata":"https://www.wikidata.org/wiki/Q412005","display_name":"Hormone receptor","level":4,"score":0.29429998993873596},{"id":"https://openalex.org/C46699223","wikidata":"https://www.wikidata.org/wiki/Q11078","display_name":"Endocrine system","level":3,"score":0.2921000123023987},{"id":"https://openalex.org/C2778292576","wikidata":"https://www.wikidata.org/wiki/Q6991934","display_name":"Neoadjuvant therapy","level":4,"score":0.2847999930381775},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.28060001134872437},{"id":"https://openalex.org/C2779974597","wikidata":"https://www.wikidata.org/wiki/Q28448986","display_name":"Clinical Practice","level":2,"score":0.27869999408721924},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.2768000066280365},{"id":"https://openalex.org/C148482608","wikidata":"https://www.wikidata.org/wiki/Q17007018","display_name":"Clinical study design","level":3,"score":0.2741999924182892},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.2741999924182892},{"id":"https://openalex.org/C2781230642","wikidata":"https://www.wikidata.org/wiki/Q492646","display_name":"Targeted therapy","level":3,"score":0.26019999384880066},{"id":"https://openalex.org/C185926286","wikidata":"https://www.wikidata.org/wiki/Q1929812","display_name":"Systemic therapy","level":4,"score":0.258899986743927},{"id":"https://openalex.org/C2779473830","wikidata":"https://www.wikidata.org/wiki/Q1540899","display_name":"MEDLINE","level":2,"score":0.25429999828338623},{"id":"https://openalex.org/C3019894029","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Overall survival","level":2,"score":0.2515000104904175}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1001/jamaoncol.2026.4471","doi":"https://doi.org/10.1001/jamaoncol.2026.4471","is_oa":false,"landing_page_url":"https://doi.org/10.1001/jamaoncol.2026.4471","pdf_url":null,"source":{"id":"https://openalex.org/S2756165422","display_name":"JAMA Oncology","issn_l":"2374-2437","issn":["2374-2437","2374-2445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320259","host_organization_name":"American Medical Association","host_organization_lineage":["https://openalex.org/P4310320259"],"host_organization_lineage_names":["American Medical Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JAMA Oncology","raw_type":"journal-article"},{"id":"pmid:42986620","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42986620","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JAMA oncology","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9922999739646912}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":38,"referenced_works":["https://openalex.org/W2120627364","https://openalex.org/W2137228442","https://openalex.org/W2144442992","https://openalex.org/W2159427817","https://openalex.org/W2159967578","https://openalex.org/W2162982444","https://openalex.org/W2166199281","https://openalex.org/W2314772071","https://openalex.org/W2551315898","https://openalex.org/W2886904628","https://openalex.org/W2998950563","https://openalex.org/W3012380787","https://openalex.org/W3192034436","https://openalex.org/W4206283263","https://openalex.org/W4290673816","https://openalex.org/W4310566600","https://openalex.org/W4313545463","https://openalex.org/W4318586343","https://openalex.org/W4321599684","https://openalex.org/W4378904902","https://openalex.org/W4380150808","https://openalex.org/W4396587506","https://openalex.org/W4398775673","https://openalex.org/W4399347358","https://openalex.org/W4402514945","https://openalex.org/W4408217434","https://openalex.org/W4409786282","https://openalex.org/W4410455673","https://openalex.org/W4411286911","https://openalex.org/W4411289028","https://openalex.org/W4412441842","https://openalex.org/W4415677336","https://openalex.org/W7119960491","https://openalex.org/W7125981927","https://openalex.org/W7128511638","https://openalex.org/W7129250477","https://openalex.org/W7129756687","https://openalex.org/W7135201180"],"related_works":["https://openalex.org/W7166682105","https://openalex.org/W4385716258","https://openalex.org/W7154591079","https://openalex.org/W7166811443","https://openalex.org/W2147874203","https://openalex.org/W2164047228","https://openalex.org/W1983451661","https://openalex.org/W2901986589","https://openalex.org/W2566325647","https://openalex.org/W4399715914"],"abstract_inverted_index":{"Importance:":[0],"The":[1,156,262],"treatment":[2,34,237,292],"landscape":[3],"of":[4,45,115,119,126,143,184,196,200,207,229,264,300,307],"ERBB2":[5,129,209],"(formerly":[6],"HER2)-positive":[7],"metastatic":[8,266],"breast":[9,267],"cancer":[10,268],"has":[11,60],"evolved":[12],"substantially":[13],"during":[14],"the":[15,22,28,43,63,86,113,124,152,194,205,215,251,298],"past":[16],"decade,":[17],"with":[18,56,73,95,141,297],"emerging":[19],"therapies":[20],"challenging":[21,256],"long-standing":[23],"induction-maintenance":[24],"paradigm":[25],"established":[26],"by":[27,69],"CLEOPATRA":[29],"trial":[30,88,154,158],"(NCT00567190).":[31],"However,":[32],"optimal":[33,117,198],"selection,":[35,293],"sequencing,":[36,296],"and":[37,49,58,105,109,123,146,181,204,218,224,245,260,281,295],"duration":[38,118,199],"remain":[39,222],"uncertain,":[40],"particularly":[41,136],"in":[42,137,151,250],"context":[44],"increasing":[46],"therapeutic":[47],"complexity":[48],"biologic":[50],"heterogeneity.":[51],"Observations:":[52],"Taxane-based":[53],"chemotherapy":[54],"combined":[55],"trastuzumab":[57,96],"pertuzumab":[59],"long":[61],"been":[62],"standard":[64],"first-line":[65],"induction":[66],"regimen,":[67],"followed":[68],"maintenance":[70,163,172],"anti-ERBB2":[71,168],"therapy":[72,77,145],"or":[74],"without":[75],"endocrine":[76,144],"based":[78],"on":[79],"hormone":[80,138],"receptor":[81],"status.":[82],"Recent":[83],"data":[84],"from":[85],"DESTINY-Breast09":[87],"(DB09;":[89],"NCT04784715)":[90],"demonstrate":[91],"superior":[92],"progression-free":[93],"survival":[94],"deruxtecan":[97],"plus":[98],"pertuzumab,":[99],"supporting":[100],"its":[101],"recent":[102],"US":[103],"Food":[104],"Drug":[106],"Administration":[107],"approval":[108],"prompting":[110],"questions":[111,192],"regarding":[112,193],"necessity":[114,195],"chemotherapy,":[116,197],"antibody-drug":[120,201],"conjugate":[121,202],"therapy,":[122,203],"role":[125,206],"a":[127,166,272],"dual":[128,208],"blockade.":[130,210],"Maintenance":[131],"strategies":[132,286],"have":[133,177],"also":[134],"expanded,":[135],"receptor-positive":[139],"disease,":[140],"incorporation":[142],"CDK4/6":[147],"inhibitors,":[148],"as":[149,242,249],"demonstrated":[150],"PATINA":[153],"(NCT02947685).":[155],"HER2CLIMB-05":[157],"(NCT05132582)":[159],"provided":[160],"an":[161],"additional":[162],"approach":[164,275],"using":[165],"triplet":[167],"strategy.":[169],"These":[170,189],"nonchemotherapy":[171],"options":[173],"are":[174,225,255],"designed":[175],"to":[176,235,290],"fewer":[178],"toxic":[179,279],"effects":[180],"better":[182],"quality":[183,306],"life":[185],"than":[186],"chemotherapy-based":[187],"strategies.":[188],"developments":[190],"raise":[191],"Emerging":[211],"biomarker-driven":[212,285],"approaches,":[213,248],"including":[214],"HER2DX":[216],"assay":[217],"circulating":[219],"tumor":[220],"DNA,":[221],"investigational":[223],"not":[226],"yet":[227],"part":[228],"routine":[230],"clinical":[231],"practice":[232],"but":[233],"aim":[234],"optimize":[236,291],"selection.":[238],"Novel":[239],"strategies,":[240],"such":[241],"chemotherapy-free":[243],"regimens":[244],"sequential":[246],"multiagent":[247],"SAPPHO":[252],"study":[253],"(NCT06439693),":[254],"traditional":[257],"paradigms.":[258],"Conclusions":[259],"Relevance:":[261],"management":[263],"ERBB2-positive":[265],"is":[269],"transitioning":[270],"toward":[271],"more":[273],"individualized":[274],"that":[276],"balances":[277],"efficacy,":[278],"effects,":[280],"patient":[282],"preferences.":[283],"Integrating":[284],"will":[287],"be":[288],"essential":[289],"duration,":[294],"goal":[299],"improving":[301],"long-term":[302],"outcomes":[303],"while":[304],"preserving":[305],"life.":[308]},"counts_by_year":[],"updated_date":"2026-11-08T12:12:28.789561","created_date":"2026-11-06T00:00:00"}